DC 371739
Alternative Names: DC-371739Latest Information Update: 23 Mar 2022
At a glance
- Originator Guangzhou JOYO Pharma
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Hyperlipidaemia
Most Recent Events
- 15 Mar 2022 Guangzhou JOYO Pharma completes a phase I trial in Hyperlipidaemia (In volunteers, In adults) in China (PO) (NCT04640012)
- 21 Dec 2021 Guangzhou JOYO Pharma completes a phase I trial in Hyperlipidaemia (In adults, In the elderly) in China (PO) (NCT04927221)
- 15 Jun 2021 Phase-I/II clinical trials in Hyperlipidaemia (In adults, In the elderly) in China (PO) (NCT04927221)